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Abstract. 
Cyclophosphamide is a widely-used alkylating agent with cytotoxic effects, as well as an 
immunosuppressive agent. In the past, life-threatening hyponatremia had been reported as a ra-
re complication induced by both high-dose and low-dose cyclophosphamide. We presented a 
breast cancer patient who had generalized seizure after the second cycle of adjuvant cyclo-
phosphamide plus epirubicin, as her serum sodium concentration dropped from 134 mmol/L to 
115 mmol/L within one day. Complete recovery was achieved after her hyponatremia was cor-
rected and we further successfully completed two additional cycles of cyclophosphamide. Cli-
nicians should always keep in mind this rare but severe adverse effect of cyclophosphamide, in 
order to make the correct diagnosis and provide prompt medical management. 
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病例報告  
Cyclophosphamide 引發之急性低血鈉症合併癲癇發生於一乳癌患者
接受輔助性 Cyclophosphamide 及 Epirubicin 之化學治療 
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中文摘要 
  Cyclophosphamide 是一種廣泛使用的化療藥物及免疫抑制劑。過去，危急生命的低血
鈉症曾被報導發生於高劑量甚至是低劑量的 cyclophosphamide。本文闡示一位乳癌患者在
接受第二次輔助化療 cyclophosphamide 合併 epirubicin 後發生大發作癲癇，而其血鈉濃度
在一天內由 134 mmol/L 降至 115 mmol/L。其神經學在血鈉矯正後即恢復正常，我們亦成
功地重試驗 cyclophosphamide 於此病人身上。臨床醫師必須謹記低劑量 cyclophosphamide
會引發此罕見卻嚴重之副作用，以便做出快速的診斷及治療。 
 
關鍵字: cyclophosphamide、低血鈉症、癲癇 
 
journal homepage:www.cos.org.tw/web/index.asp
台灣癌症醫誌 (J. Cancer Res. Pract.) 2(2), 157-161, 2015 DOI: 10.6323/JCRP.2015.2.2.07
Open access under CC BY-NC-ND license.
INTRODUCTION 
Cyclophosphamide is a widely-used alkylating 
agent for the treatment of both hematologic and solid 
malignancies, including but not limited to lymphoma, 
leukemia, multiple myeloma, breast cancer, neuro-
blastoma and retinoblastoma. It is also a strong im-
munosuppressant commonly utilized for dealing with 
serious manifestations of autoimmune diseases. 
Moreover, this drug has now widely emerged as a 
mobilization regimen in peripheral stem cell harvest-
ing and as a part of a conditioning regimen in al-
logenous stem cell transplantation. The most common 
short-term side effects include nausea, vomiting, diar-
rhea, alopecia, darkening of the skin and nails, hem-
orrhagic cystitis and bone marrow suppression. It’s 
long term potential toxicities consist of pulmonary 
fibrosis, infertility, teratogenesis and carcinogenesis.  
Hyponatremia resulting from impaired water ex-
cretion had been reported in some patients treated with 
cyclophosphamide [1]. The severity of hyponatremia 
was correlated with the dosage of the drug, which was 
more commonly seen in high (30~40 mg/kg) and in-
termediate doses (20~30 mg/kg). Therefore, general-
ized seizure caused by severe hyponatremia is consid-
ered a very rare complication of low dose (<15 mg/kg) 
cyclophosphamide. We herein reported the case of a 
patient developing symptomatic hyponatremia during 
the course of adjuvant chemotherapy for breast cancer.  
 
CASE REPORT 
A 57-year-old female was diagnosed with invasive 
left breast ductal carcinoma, pT1cN0M0, stage I in 
Sept. 2013. After having breast-conserving surgery 
and sentinel lymph node dissection on Sep. 24th, 2013, 
she was scheduled to receive four cycles of EC (cy-
clophosphamide 600 mg/m2 on D1 and epirubicin 90 
mg/m2 on D1) every 3 weeks as adjuvant chemother-
apy. At that time, she was 156.4 cm tall and weighed 
57.8 kg, with underlying hypertension and type 2 dia-
betes mellitus and long-term medication as follows: 
losartan, amlodipine, glimepiride, and metformin. The 
patient took telbivudine and was also a hepatitis B 
carrier. The first cycle of chemotherapy consisting of 
cyclophosphamide 960 mg and epirubicin 140 mg and 
total 0.9% sodium chloride 1750 mL was performed 
without incident on Oct, 22th, 2013. However, she felt 
progressive dizziness on the second day of cycle two 
of the chemotherapy on Nov. 13th, 2013, and devel-
oped generalized tonic-clonic convulsion the next day. 
Her vital signs upon arrival at the other local hospi-
tal’s emergency department were temperature 36˚C, 
pulse rate 80 beats/min, respiratory rate 16/min and 
blood pressure 137/ 84 mmHg. There was no focal 
neurologic sign upon physical examination. Her 
hemogram was as noted: white blood cell count 
12050/uL, hemoglobin 13.8 g/dL and platelet count 
366 x 103/uL. The patient’s serum biochemistry re-
vealed sodium 115 mmol/L, potassium 3.47 mmol/L, 
calcium 8.97 mg/dL, albumin 4.99 g/dL, blood urea 
nitrogen 10 mg/dL, creatinine 1.04 mg/dL, glucose 
254 mg/dL and ammonia 38 mg/dL. Her serum sodi-
um level before the second cycle of chemotherapy was 
134 mmol/L in November, 2013. The electrocardio-
gram showed normal sinus rhythm. Additionally, 
computed tomography did not identify any organic 
lesion. She was euvolemic and further adrenal func-
tion (cortisol: 23 μg/dL, ACTH: 22.7 pg/mL) and thy-
roid function (free T4: 1.52 ng/dL, TSH: 0.718 μIU/ 
mL) were both within normal limits. However, when 
the patient was placed on a 3% sodium chloride sup-
plement, her serum sodium level gradually corrected 
to 137 mmol/L on Nov. 15th, 2013, and she was dis-
charged without any neurological sequelae. She fur-
ther completed the third and fourth cycles of adjuvant 
EC chemotherapy without dose reduction on Dec. 4th 
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and Dec. 25th, 2013, respectively, on an inpatient basis. 
Serial monitoring of serum sodium level indeed 
showed acute hyponatremia occurring on the second 
day of chemotherapy from 137 mmol/L to 126 
mmol/L during the cycle 3 chemotherapy, which was 
corrected by timely normal saline infusion. This situa-
tion was even moreso improved during the cycle 4 
chemotherapy due to the additional infusion of normal 
saline based on our prior experience as the serum so-
dium level declined from 139 mmol/L to 130 mmol/L 
only. The symptom of nausea was also substantially 
improved after the saline infusion.  
 
DISCUSSION 
In the case of our subject, we presented a breast 
cancer patient developing acute severe hyponatremia 
complicated with generalized seizure after the second 
cycle of cyclophosphamide. It is not unusual for a pa-
tient to manifest fatigue, nausea, lethargy, or muscle 
cramps when serum sodium decreases below 125 
mmol/L. If left untreated, the patient’s neurological 
deficit may deteriorate to seizure, psychosis or even 
coma when serum sodium is below 115 mmol/L. Oth-
er possible causes resulting in seizure in this case had 
been excluded by normal electrocardiogram, normal 
brain image, and normal biochemistry except for se-
rum sodium concentration. Most importantly, her 
neurological symptoms recovered completely after 
correction of the sodium level. The cause and effect 
between cyclophosphamide and hyponatremia was 
further illustrated by a rechallenge of the drug. Fortu-
nately, once the patient was under proper management, 
she didn’t experience another episode of seizure.  
Life-threatening hyponatremia could be induced 
by high-dose (30 to 40 mg/kg) and moderate-dose (20 
to 30 mg/kg) cyclophosphamide in stem cell trans-
plantation patients. Albeit rare, this adverse effect 
could be seen in patients, either with malignancy or 
non-malignancy diseases, who were treated with 
low-dose (<15 mg/kg) cyclophosphamide. These re-
ports were summarized in Table 1 and Table 2. In 
most cases, hyponatremia occurred in the 1st or 2nd 
cycles of cyclophosphamide administration. Besides, 
based on the good bioavailability of the drug, even 
very low dose oral form can evoke the same depth of 
hyponatremia as intravenous form. 
The mechanism of cyclophosphamide-induced 
hyponatremia is still ambiguous. Harlow et al. made a 
Table 1. Published report of hyponatremia induced by cyclophosphamide (malignant diseases) 
Disease Age/Sex Cyclophosphadmide 
dosage 
Serum 
sodium 
Precipitating factor Reference
Multiple myeloma 68/M 500 mg iv 108 Concomitant use of 
indomethacin 
2 
Breast cancer 64/F 1st cycle 500 mg/m2 iv 107 - 6 
Metastatic adenoCA of 
salivary gland 
69/F 2nd cycle 500 mg/m2 iv 116 Concomitant use of 
cisplatin 
3 
Breast cancer 56/F 1st cycle 600 mg/m2 iv 116 Concomitant use of 
cisplatin and ACEi 
4 
Multiple myeloma 69/F 1st cycle 500 mg po 113 - 5 
Breast cancer 54/F 
58/F 
1st cycle 500 mg/m2 
1st cycle 500 mg/m2 
120 
124 
- 7 
Breast cancer 57/F 2nd cycle 600 mg/m2 iv 115 - Our case 
(adenoCA:adenocarcinoma, ACEi:angiotensin converting enzyme inhibitor) 
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hypothesis of inability of excretion of diluted urine by 
kidney, i.e SIADH. Loss of Herring’s bodies and 
degranulation of hypothalamic neurosecretory orga-
nelles was demonstrated by autopsy in one case using 
high-dose cyclophosphamide [13]. Others assumed 
that cyclophosphamide or its metabolite may increase 
the release of vasopressin or have direct toxic effect 
on renal collecting duct epithelium [2,14]. Further 
studies may be necessary to illustrate that the drug 
reaction is idiosyncratic or concentration-dependent 
effect. 
Some precipitating factors of cyclophosphamide- 
induced hyponatremia mentioned in previous pub-
lished case reports consisted of overhydration, con-
comitant drug use and renal failure [2-12]. Apart from 
cyclophosphamide, other cytotoxic agents used as part 
of a combination regimen may make a patient prone to 
SIADH and hyponatremia , including vincristine, vin-
blastine, busulfan, chlorambucil, cisplatin, cytarabine, 
fludarabine, hydroxyurea, melphalan, thiotepa, 
alemtuzumab, bevacizumab, bortezomib, imatinib, 
interferon alfa, and ifosfamide [15-17]. Underlying 
diseases or condition might also predispose a patient 
to develop SIADH, such as old-age, underweight sta-
tus, female, pulmonary diseases or malignancy [18]. 
With our patient, although sulfonylurea had been re-
ported to cause SIADH [19], this medication had been 
used for more than 3 years without occurrence of any 
hyponatremia-induced neurologic event. Despite the 
lack of urine osmolality data, the syndrome of inap-
propriate antidiuretic hormone secretion was most 
likely associated with the diagnosis of her hypo-
natremia since she was euvolemic with normal thyroid 
and adrenal function. And it showed that only cyclo-
phosphamide per se would be the most reasonable 
cause resulting in severe hyponatremia. Compared 
with the other case reports, in which hyponatremia 
was managed with free water restriction, 3% saline or 
discontinuation of cyclophosphamide, our case was 
successfully rechalleneged with the two additional 
cycles of cyclophosphamide, without dose reduction, 
under the aid of only 0.9% normal saline supplement. 
It might imply that cyclophosphamide-induced renal 
toxicity is transient.  
In conclusion, physicians should be aware of this 
rare but life-threatening adverse effect in patients re-
ceiving even low-dose cyclophosphamide. Hypo-
natremia is one of the differential diagnoses for those 
patients who present with fatigue, lethargy or altera-
tion of consciousness. However, only early detection 
and prompt management would prevent the patient 
from irreversible neurologic insults.  
Table 2. Published report of hyponatremia induced by cyclophosphamide (non-malignant diseases) 
Disease Age/Sex Cyclophosphadmide 
dosage 
Serum 
sodium 
Precipitating factor Reference
SLE 59/F 10 mg/kg, iv 116 - 12 
Sjogren’s disease 57/F 780 mg, iv 117 - 13 
SLE 48/F 
53F 
750 mg, iv 
500 mg, iv 
119 
119 
- 8 
ANCA-related GN 70/F 50 mg, po 108 Renal failure 9 
Polyarteritis nodosa 46/F 15 mg/kg, iv 112 High fluid intake 10 
SLE 30/F 15 mg/kg, iv 106 Lupus nephritis, high 
fluid intake 
10 
Systemic sclerosis 49/F 2nd cycle 500 mg, iv 106 - 11 
(SLE:systemic lupus erythematosus, ANCA: antineutrophil cytoplasmic autoantibodies) 
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